best peptides FAQ

TB-500 has a half-life of several days, so missing one dose in a twice-weekly protocol does not reset progress. Administer the missed dose as soon as you remember if fewer than 3 days have passed, then resume your regular schedule. If more than 3 days have passed, skip the missed dose and continue on your next scheduled date. Do not double-dose. Loading phase consistency matters more than maintenance phase precision.

Serum ferritin below 75 ng/mL predicts poor RLS treatment response. Even if hemoglobin is normal. A 2022 trial in Sleep Medicine found oral iron supplementation (325 mg ferrous sulfate with 100 mg vitamin C daily) improved RLS severity by 40% in patients with ferritin 15–75 ng/mL over 12 weeks. If iron repletion alone resolves symptoms, peptides become unnecessary. The decision tree: measure ferritin first; if low, supplement iron for three months and reassess; if symptoms persist despite ferritin above 75 ng/mL, then dopamine agonists or peptides warrant consideration. Iron is cheaper, safer, and evidence-based. Exhaust this option before investigational peptides.

Growth hormone secretagogues like CJC-1295/ipamorelin operate through entirely different pathways and do not cause gastric side effects. The trade-off: they require active caloric management. GLP-1 agonists reduce intake passively; HGH secretagogues shift what gets burned without suppressing appetite. If nausea prevents GLP-1 use, pair CJC-1295/ipamorelin with structured deficit tracking. Tesofensine is oral and avoids GI mechanisms, but lacks Phase 3 safety data.

Reduce training volume by 40–50% during the first three weeks of peptide administration. Continuing full stroke count recreates the microtrauma faster than peptides can repair it. BPC-157 and TB-500 accelerate collagen synthesis, but newly formed tissue requires 14–21 days to achieve mechanical strength sufficient for competitive loading. The injury-recovery-reinjury cycle happens when swimmers maintain 30,000+ strokes per week while expecting peptides to compensate. Research shows peptide-assisted athletes who reduced volume during active treatment returned to competition 6 weeks faster than those who pushed through pain with peptides alone.

Start TB-500 immediately if you're in weeks 8–16. This is the proliferative phase when it's most effective. Collagen peptides provide benefit at any point during the first year post-surgery because tissue remodeling continues through month 12. BPC-157's anti-inflammatory effects are most pronounced during acute inflammation (weeks 0–6), but patients with persistent swelling at week 8+ still see benefit from reducing chronic low-grade inflammation that interferes with tissue maturation. The optimal peptide window is early, but late administration still outperforms no peptide support.

Cartalax stabilises mitochondrial DNA and reduces new oxidative lesions, but it does not reverse established mtDNA mutations. Those are permanent unless the affected mitochondria are cleared through mitophagy (selective autophagy of damaged mitochondria). What Cartalax does is prevent further accumulation in healthy mitochondria and support TFAM-mediated transcription in partially damaged genomes, which can improve ATP output even with some baseline mutation load. If mitochondrial dysfunction is severe, combining Cartalax with mitophagy inducers (urolithin A, spermidine) may be more effective than Cartalax alone.

Chronic tendinitis indicates the injury never transitioned from the inflammatory phase to the proliferative phase. Start TB-500 at 10mg twice weekly for four weeks to reset the inflammatory cascade, then add BPC-157 at 250 micrograms daily for localized repair. Training volume must drop by 40–50% during the first two weeks to allow the peptide-driven repair process to outpace ongoing damage accumulation.

Add Selank at 600 mcg intranasal twice daily. If anxiety persists beyond 72 hours at therapeutic peptide doses, the underlying withdrawal syndrome may require pharmaceutical GABAergic support (clonidine, gabapentin) in addition to peptide protocols. Peptides reduce severity. They don't eliminate all symptoms in severe cases.

Reassess the failure point before adjusting dose or switching compounds. Order repeat hormone panels (LH, FSH, total and free testosterone, estradiol, prolactin) and semen analysis to determine if the peptide corrected the targeted mechanism but another bottleneck remains. If LH and testosterone normalized but sperm concentration stayed flat, the issue may be primary testicular pathology (varicocele, Y-chromosome microdeletion, post-infectious tubular damage) that no upstream hormone modulation will fix. Continuing the same peptide at higher doses rarely overcomes structural testicular defects.

Mild swelling is common with subcutaneous peptide administration and typically resolves within 24–48 hours. If swelling persists beyond 72 hours or is accompanied by warmth and redness, suspect contamination or an immune response to inactive ingredients (reconstitution solvent, preservatives). Switch to a different bacteriostatic water source and verify sterile technique. Persistent adverse reactions require discontinuation.

Adding MK 677 at 12.5–25mg daily creates a systemic anabolic environment through elevated IGF-1 and improved sleep architecture, which supports overall tissue recovery without targeting the rotator cuff specifically. Stacking more than three peptides simultaneously (BPC-157 + TB-500 + one systemic compound) introduces diminishing returns. Receptor saturation limits how much additional healing you can drive. Our experience shows the BPC-157/TB-500 combination covers the critical localized mechanisms, while a GH secretagogue like MK 677 optimizes the systemic recovery backdrop. Adding further compounds increases injection complexity and cost without proportional benefit.

Missing BPC-157 doses during the acute inflammatory phase (days 0–7) extends recovery time but doesn't eliminate benefit. Resume dosing immediately and extend the protocol by the number of missed days. TB-500's twice-weekly schedule offers more flexibility: if you miss a dose, administer it as soon as you remember and continue the regular schedule. Missing more than 4 consecutive days of BPC-157 during acute inflammation may require restarting the inflammatory phase clock, particularly for Grade 2+ strains.

Administer a growth hormone secretagogue like MK-677 rather than a GnRH analog. Normal gonadotropins suggest the pituitary is signaling appropriately, but downstream testosterone synthesis or peripheral metabolism is impaired. MK-677 increases IGF-1, which supports Leydig cell steroidogenesis and improves insulin sensitivity that can amplify testosterone production without further LH stimulation. Kisspeptin or gonadorelin would over-stimulate an already-functioning pituitary and risk receptor desensitization.

A weight loss plateau on GLP-1 agonists typically signals metabolic adaptation. Your body has reduced non-exercise activity thermogenesis (NEAT) and basal metabolic rate in response to sustained caloric deficit. The solution is not to increase the peptide dose beyond therapeutic levels; it's to introduce a structured diet break (two weeks at maintenance calories) or add a thermogenic compound like tesofensine to raise resting energy expenditure. Semaglutide's appetite suppression remains effective, but if energy expenditure has dropped 200–300 calories per day, the deficit you started with no longer exists.

Stop alpha-lipoic acid supplementation at least one week before and two weeks after dental amalgam removal. ALA crosses the blood-brain barrier efficiently and chelates mercury in plasma. But if mercury vapour from drilling increases blood mercury acutely, ALA redistributes that mercury into the CNS before it can be renally cleared. The International Academy of Oral Medicine and Toxicology explicitly contraindicates ALA during active amalgam procedures. Resume ALA only after confirming plasma mercury has returned to baseline, typically 10–14 days post-removal.

Lyophilized peptides should appear as white to off-white powder with no discoloration, clumping, or moisture. If the vial contains liquid, the product was not properly lyophilized or has been compromised during storage. Peptides are temperature-sensitive. Any excursion above 8°C during shipping or storage can denature the amino-acid structure, rendering the compound inactive without visible signs of degradation. Real Peptides ships all research peptides with cold-chain verification and batch-specific HPLC purity reports. If your product lacks documentation or arrived warm, contact the supplier before reconstitution.

Discard it immediately. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the compound biologically inactive and potentially harmful. Properly reconstituted BPC-157, TB-500, and GHK-Cu should be crystal-clear with no particulate matter. Aggregation happens when peptides are reconstituted with non-bacteriostatic water, exposed to temperature excursions above 25°C during shipping, or shaken violently instead of gently swirled. Real Peptides provides reconstitution protocols with every peptide shipment. Following them prevents the single most common preparation error that wastes expensive compounds.

Skip the 14-day metallothionein priming phase and you mobilise metals from tissue storage without adequate intracellular binding proteins to sequester them safely. Research from the Journal of Trace Elements shows that chelation initiated without MT upregulation increases plasma mercury by 40–60% transiently as metals redistribute from liver and bone to circulation. And a portion crosses the blood-brain barrier before renal excretion occurs. The correct sequence: zinc-methionine 30–50mg daily for two weeks, verify plasma zinc is 80–120 mcg/dL, then introduce chelation while continuing zinc. Chelation without priming is redistribution, not detoxification.

Reduce injection volume and frequency. Irritation often results from injecting more than 0.5 mL subcutaneously in one site or hitting the same injection location repeatedly within 48 hours. Rotate injection sites by at least 2 inches between doses, staying within the general injury proximity (2–3 inches from the affected ligament). If redness persists beyond 24 hours or is accompanied by warmth and swelling, discontinue use and evaluate for allergic reaction or contamination. Persistent irritation can also indicate incorrect reconstitution concentration. Verify you're using the intended bacteriostatic water volume (typically 2–3 mL per vial). Never inject directly into inflamed tissue; target healthy subcutaneous fat adjacent to the injury zone.

Do not inject directly into the tendon itself. Tendon tissue has minimal vascularity and injecting into dense collagen fibers risks mechanical damage or localized hematoma. Inject subcutaneously 2–3 centimeters proximal or distal to the lateral epicondyle. The peptide circulates locally and reaches the injury site through capillary diffusion without requiring intra-tendon placement.